Curated News
By: NewsRamp Editorial Staff
June 10, 2025

VERAXA Biotech AG and Voyager Acquisition Corp. Merge in $1.64B Deal

Reddit Discuss on LinkedIn Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • VERAXA Biotech AG's merger with Voyager Acquisition Corp. offers investors a unique opportunity to capitalize on a $1.64 billion valuation and access to cutting-edge cancer therapies.
  • The merger between VERAXA Biotech AG and Voyager Acquisition Corp. involves a $253 million trust fund and a crossover round, aiming for NASDAQ listing under VERX by Q4 2025.
  • VERAXA Biotech AG's innovative BiTAC platform and pipeline of nine cancer therapy programs promise to advance treatment options and improve patient outcomes globally.
  • Discover how VERAXA Biotech AG's bispecific ADCs and T cell engagers are revolutionizing cancer treatment, backed by a $1.64 billion merger with Voyager Acquisition Corp.

Impact - Why it Matters

This merger represents a significant advancement in cancer therapy, offering hope for more effective treatments through VERAXA's innovative BiTAC platform. The collaboration not only accelerates the development of cutting-edge therapeutics but also highlights the growing importance of strategic partnerships in advancing medical research and patient care. For investors and the healthcare industry, this deal underscores the potential for substantial returns and breakthroughs in treating complex diseases.

Summary

VERAXA Biotech AG, a pioneering force in cancer therapy and the proposed de-SPAC target of Voyager Acquisition Corp. (NASDAQ: VACH), has announced a definitive merger agreement valuing the combined entity at approximately $1.64 billion. This strategic move is set to propel VERAXA onto the NASDAQ under the ticker symbol "VERX," marking a significant milestone in its mission to revolutionize cancer treatment through its Bi-Targeted Antibody Cytotoxicity (BiTAC) platform. With a robust pipeline featuring nine programs, including an active Phase 1 trial in leukemia, VERAXA is at the forefront of developing next-generation antibody-based therapeutics. Backed by majority shareholders Xlife Sciences AG, EMBL, and EMBLEM, and led by CEO Christoph Antz, Ph.D., and CBO Heinz Schwer, Ph.D., MBA, VERAXA is poised for unprecedented growth. Voyager Acquisition Corp. is contributing up to $253 million from its trust account to fuel this venture, with the merger expected to close by Q4 2025. For more details, visit the full press release.

VERAXA's innovative approach to cancer therapy, including bispecific ADCs and T cell engagers, is underpinned by its proprietary BiTAC platform and a commitment to quality-by-design principles. Founded on groundbreaking research from the European Molecular Biology Laboratory, VERAXA is rapidly advancing its clinical pipeline. The merger with Voyager Acquisition Corp., advised by Anne Martina Group, signifies a bold step forward in the healthcare sector, aiming to scale new heights in medical innovation. Discover more about VERAXA's vision at www.veraxa.com and Voyager's mission at https://www.voyageracq.com.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VERAXA Biotech AG and Voyager Acquisition Corp. Merge in $1.64B Deal

blockchain registration record for this content.